NCT05142306View on ClinicalTrials.gov

A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

December 7, 2021

Primary Completion Date

March 28, 2022

Study Completion Date

May 31, 2022

Conditions
SARS-CoV-2 Infection
Interventions
BIOLOGICAL

COVID-HIG

Anti-SARS-CoV-2 Immunoglobulin (Human) \[COVID-HIG\] is a purified liquid immunoglobulin G (IgG) preparation

Trial Locations (2)

33143

Qps-Mra, Llc, Miami

65802

Bio-Kinetic Clinical Applications, LLC, Springfield

Sponsors
All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Emergent BioSolutions

INDUSTRY